SAN DIEGO, Oct. 11, 2022 (GLOBE NEWSWIRE) — The Shareholders Foundation, Inc. announces that a lawsuit is pending for certain investors in shares of Lottery.com Inc. (NASDAQ: LTRY).
Investors who purchased Lottery.com Inc. (NASDAQ: LTRY) shares have certain options and should contact the Shareholders Foundation at firstname.lastname@example.org or call +1(858) 779 – 1554.
On August 22, 2022, a lawsuit was filed against Lottery.com Inc. over alleged Securities Laws Violations. The plaintiff alleges that the Defendants made false and/or misleading statements and/or failed to disclose that, inter alia the Company lacked adequate internal accounting controls, that the Company lacked adequate internal controls over financial reporting, including but not limited to those pertaining to revenue recognition and the reporting of cash, that the Company was not in compliance with state and federal laws governing the sale of lottery tickets, and that as a result, the Company’s public statements were materially false and misleading at all relevant times.
Those who purchased Lottery.com Inc. (NASDAQ: LTRY) shares should contact the Shareholders Foundation, Inc.
Shareholders Foundation, Inc.
+1 (858) 779-1554
3111 Camino Del Rio North
San Diego, CA 92108
The Shareholders Foundation, Inc. is a professional portfolio legal monitoring and a settlement claim filing service, which does research related to shareholder issues and informs investors of securities class actions, settlements, judgments, and other legal related news to the stock/financial market. The Shareholders Foundation, Inc. is not a law firm. Any referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is only provided as a public service. It is not intended as legal advice and should not be relied upon.
- FTCH INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Announces that Farfetch Limited Investors with Substantial Losses Have Opportunity to Lead Case - December 9, 2023
- Cogent Biosciences Announces Positive Initial Data from Phase 2 SUMMIT Trial Evaluating Bezuclastinib in Patients with Nonadvanced Systemic Mastocytosis (NonAdvSM) - December 9, 2023
- FSR INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Announces that Fisker Inc. Investors with Substantial Losses Have Opportunity to Lead Case - December 9, 2023